Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
Relja Popovic(Loyola University Medical Center), Brenda Chyla(AbbVie (United States)), Stephan Stilgenbauer(Universität Ulm), Eugen Tausch(Universität Ulm), Scott E. Warder(AbbVie (United States)), Jeremy A. Ross(AbbVie (United States)), Kenneth P. Robinson(AbbVie (United States)), Nabanita Mukherjee(AbbVie (United States)), Matthew S. Davids(Dana-Farber Cancer Institute), John C. Pesko(AbbVie (United States)), Joel D. Leverson(AbbVie (United States)), Danjuma Quarless(AbbVie (United States)), Jeffrey F. Waring(AbbVie (United States)), Su Young Kim(Yonsei University), Andrew J. Souers(AbbVie (United States)), Charles Lu(The University of Texas MD Anderson Cancer Center), Fengjiao Dunbar(AbbVie (United States))
Cited by 19
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k